Table 1 Baseline characteristics of patients randomised to the two groups.
Intermittent (n = 84) | Continuous (n = 85) | |
|---|---|---|
Age at recruitmenta | 51.2 (31–71) | 52.6 (24–77) |
BMI at recruitment (kg/m2)b | 28.0 (6.2) | 28.2 (6.1) |
BMI categoryc | ||
Healthy weight (19.0–24.9 kg/m2) | 31 (36.9%) | 29 (34.1%) |
Overweight (25–29.9 kg/m2) | 28 (33.3%) | 31 (36.5%) |
Obese (≥30 kg/m2) | 25 (29.8%) | 25 (29.4%) |
Charlson Co-morbidity Index scoreb | 2.2 (0.4) | 2.1 (0.4) |
Score ≤2c | 71 (84.5%) | 76 (89.4%) |
Score >2c | 13 (15.5%) | 9 (10.6%) |
Current smokerc | 6 (7.1%) | 3 (3.5%) |
Menopausal statusc | ||
Pre or peri/post | 46 (54.8%)/38 (45.2%) | 44 (51.8%)/41 (48.2%) |
First-degree relative with BCc | 20 (23.8%) | 17 (20%) |
Screen detected BCc | 21 (25.0%) | 20 (23.5%) |
Days between final breast surgery and randomisationd | 35 (9–72) | 34 (18–174) |
Tumour type and gradec | ||
Grade 3 carcinoma | 54 (64.3%) | 44 (51.8%) |
Oestrogen receptor positive | 59 (70.2%) | 54 (63.5%) |
HER2 receptor positive | 19 (22.6%) | 29 (34.1) |
Triple negative | 16 (19%) | 16 (18.8%) |
Surgery typec | ||
Mastectomy | 35 (41.7%) | 36 (42.4%) |
Axillary node clearance | 39 (46.4%) | 39 (45.9%) |
Chemotherapy regimenc | ||
Adjuvant/neoadjuvant | 79/5 (94%/6%) | 79/6 (94%/6%) |
F(EC) and docetaxel/paclitaxel | 81 (96.4%) | 76 (89.4%) |
Other, e.g. carboplatin or cyclophosphamide and docetaxel | 3 (3.6%) | 9 (10.6%) |
Prophylactic G-CSF treatmente | 84 (100%) | 85 (100%) |
Number of chemotherapy cycles | 6 (4–10) | 6 (4–8) |
Ethnicityc | ||
White—all types | 79 (94.0%) | 78 (91.8%) |
Other | 5 (6.0%) | 7 (8.2%) |
Social circumstancec | ||
Married or co-habiting | 64 (76.2%) | 62 (72.9%) |
Children living at home | 45 (53.6%) | 42 (49.4%) |
Educationc | ||
Educated to degree level or above | 27 (32.1%) | 27 (31.7%) |
Employment | ||
Full- or part-time employment | 58 (69.0%) | 63 (74.1 %) |
Retired or unemployed | 26 (31.0%) | 21 (24.7%) |
Index of multiple deprivationc,f | ||
England quintiles | ||
1 (least deprived) | 19 (22.6%) | 17 (20.0%) |
2 | 23 (27.4%) | 23 (27.1%) |
3 | 14 (16.7%) | 16 (18.8%) |
4 | 13 (15.5%) | 13 (15.3%) |
5 (most deprived) | 15 (17.9%) | 16 (18.8%) |
